Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH.

Arch Neurol. 2011 Apr;68(4):464-8. doi: 10.1001/archneurol.2011.45.

PMID:
21482925
2.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators..

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
3.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators..

Neurology. 2007 Oct 2;69(14):1391-403.

PMID:
17761550
4.

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.

Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS.

Mult Scler. 2004 Oct;10(5):511-20.

PMID:
15471366
5.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators..

N Engl J Med. 2006 Mar 2;354(9):911-23.

6.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators..

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012.

PMID:
20236661
7.

Health-related quality of life in multiple sclerosis: effects of natalizumab.

Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators..

Ann Neurol. 2007 Oct;62(4):335-46.

PMID:
17696126
8.

Clinical evaluation of natalizumab for formulary consideration.

Bivins A, Hou K, Ayesu N, Ellsworth B Jr, Montenegro S, Tu X, Boyle C, Dowling T, Shaya FT.

Expert Opin Biol Ther. 2010 Aug;10(8):1279-87. doi: 10.1517/14712598.2010.505234. Review.

PMID:
20626228
9.

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA.

Neurology. 2007 Apr 17;68(16):1299-304.

PMID:
17438220
10.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
11.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFN╬▓-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304.

PMID:
22194217
12.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.

J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7.

PMID:
22008873
13.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147.

PMID:
20488825
14.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
15.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204.

PMID:
18071030
16.
17.

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.

Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909.

PMID:
20150398
18.

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.

Berger JR.

Mult Scler. 2008 Jun;14(5):708-10. doi: 10.1177/1352458507087135.

PMID:
18566035
19.
20.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
Items per page

Supplemental Content

Support Center